3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Fallopian Tube Neoplasms
5
Ovarian Neoplasms
4
Carcinoma, Ovarian Epithelial
3
Neoplasms
2
Recurrence
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Metastatic Castration Resistant Prostate Cancer
1
Genital Neoplasms, Male
1
Adenocarcinoma, Clear Cell
1
Interventions
Cyclophosphamide
3
Epirubicin
2
Docetaxel
2
Carboplatin
2
Capecitabine
2
Azacitidine
2
venetoclax
1
tegafur-gimeracil-oteracil
1
taxane
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pirarubicin
1
pertuzumab
1
pembrolizumab
1
olaparib
1
cc-486
1
Trastuzumab
1
Thalidomide
1
Radiotherapy
1
Radiation
1
Platinum
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Methotrexate
1
Magnetic Resonance Imaging
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pathologic Complete Response
×
rucaparib
×
Clear all
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts